[go: up one dir, main page]

ATE380187T1 - Agonisten und antagonisten für den lpa-rezeptor und anwendungsmethoden - Google Patents

Agonisten und antagonisten für den lpa-rezeptor und anwendungsmethoden

Info

Publication number
ATE380187T1
ATE380187T1 AT01922465T AT01922465T ATE380187T1 AT E380187 T1 ATE380187 T1 AT E380187T1 AT 01922465 T AT01922465 T AT 01922465T AT 01922465 T AT01922465 T AT 01922465T AT E380187 T1 ATE380187 T1 AT E380187T1
Authority
AT
Austria
Prior art keywords
methods
agonists
antagonists
lpa
lpa receptor
Prior art date
Application number
AT01922465T
Other languages
English (en)
Inventor
Duane Miller
Gabor Tigyi
James Dalton
Vineet Sardar
Don Elrod
Huiping Xu
Daniel Baker
Dean Wang
Karoly Liliom
David Fischer
Tamas Virag
Nora Nusser
Original Assignee
Univ Tennessee Res Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Res Corp filed Critical Univ Tennessee Res Corp
Application granted granted Critical
Publication of ATE380187T1 publication Critical patent/ATE380187T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4025Esters of poly(thio)phosphonic acids
    • C07F9/4028Esters of poly(thio)phosphonic acids containing no further substituents than -PO3H2 groups in free or esterified form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/091Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/093Polyol derivatives esterified at least twice by phosphoric acid groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/094Esters of phosphoric acids with arylalkanols
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/098Esters of polyphosphoric acids or anhydrides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/11Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/16Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165Esters of thiophosphoric acids
    • C07F9/17Esters of thiophosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/222Amides of phosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01922465T 2000-03-17 2001-03-19 Agonisten und antagonisten für den lpa-rezeptor und anwendungsmethoden ATE380187T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19037000P 2000-03-17 2000-03-17

Publications (1)

Publication Number Publication Date
ATE380187T1 true ATE380187T1 (de) 2007-12-15

Family

ID=22701059

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01922465T ATE380187T1 (de) 2000-03-17 2001-03-19 Agonisten und antagonisten für den lpa-rezeptor und anwendungsmethoden

Country Status (13)

Country Link
US (2) US6875757B2 (de)
EP (2) EP1918287A3 (de)
JP (1) JP2004506604A (de)
KR (1) KR100874392B1 (de)
AT (1) ATE380187T1 (de)
AU (1) AU4926301A (de)
CA (1) CA2402038C (de)
CY (1) CY1107214T1 (de)
DE (1) DE60131730T2 (de)
DK (1) DK1263752T3 (de)
ES (1) ES2298227T3 (de)
PT (1) PT1263752E (de)
WO (1) WO2001071022A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130237A1 (en) * 2000-03-17 2003-07-10 Miller Duane D. LPA receptor agonists and antagonists and methods of use
KR100874392B1 (ko) * 2000-03-17 2008-12-17 유니버시티 오브 테네시 리서치 파운데이션 Lpa 수용체 아고니스트 및 안타고니스트, 및 사용 방법
EP1361872A4 (de) 2000-10-03 2004-05-19 Univ Virginia Neue lysophosphatsäurerezeptor-agonisten und -antagonisten
US7064217B2 (en) 2001-01-30 2006-06-20 University Of Virginia Patent Foundation Agonists and antagonists of sphingosine-1-phosphate receptors
JP4396808B2 (ja) * 2001-02-08 2010-01-13 小野薬品工業株式会社 Lpa受容体調節剤からなる泌尿器疾患治療剤
ATE406915T1 (de) * 2001-07-17 2008-09-15 Ono Pharmaceutical Co Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler
WO2003068931A2 (en) * 2002-02-13 2003-08-21 The Scripps Research Institute Purification of the leading front migratory cells
US7285680B2 (en) 2002-05-28 2007-10-23 Ono Pharmaceutical Co., Ltd. β-alanine derivatives and the use thereof
US7300764B2 (en) 2002-06-08 2007-11-27 Sanofi-Aventis Deutschland Gmbh Method for identifying agonists and antagonists of the GPR45-like/GPR63 receptor
DE10225651A1 (de) * 2002-06-08 2003-12-24 Aventis Pharma Gmbh Verfahren zur Identifizierung von Agonisten oder Antagonisten für den GPR45like/GPR63 Rezeptor
TW200400930A (en) * 2002-06-26 2004-01-16 Ono Pharmaceutical Co Therapeutic agent for chronic disease
US7241790B2 (en) * 2002-07-30 2007-07-10 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
WO2004044588A1 (en) * 2002-11-13 2004-05-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with endothelial differentiation, sphingolipid g-protein-coupled receptor 4 (edg4)
WO2004052391A1 (ja) * 2002-12-12 2004-06-24 Takeda Pharmaceutical Company Limited Edg受容体の新規用途
US7524638B1 (en) 2003-06-27 2009-04-28 Osi Pharmaceuticals, Inc. Methods for identification of modulators of OSGPR114 or OSGPR78 activity, and their use in the treatment of disease
WO2005009469A1 (ja) * 2003-07-28 2005-02-03 Sumitomo Pharmaceuticals Co., Ltd. 新規血糖調節薬及びそのスクリーニング方法
JP5048333B2 (ja) * 2003-10-09 2012-10-17 ユニバーシティ オブ テネシー リサーチ ファウンデーション Lpa受容体アゴニストおよびアンタゴニストならびに使用法
US7638637B2 (en) * 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
US7820703B2 (en) 2004-05-06 2010-10-26 University Of Virginia Patent Foundation Lysophosphatidic acid receptor selective antagonists
US20060223866A1 (en) * 2004-08-13 2006-10-05 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
AU2005272619A1 (en) * 2004-08-13 2006-02-23 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (SIP) receptor activity
US7888527B2 (en) * 2004-12-06 2011-02-15 University Of Virginia Patent Foundation Aryl amide sphingosine 1-phosphate analogs
WO2006088944A1 (en) 2005-02-14 2006-08-24 University Of Virginia Patent Foundation Sphingosine 1- phos phate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups
WO2007011905A2 (en) 2005-07-19 2007-01-25 The University Of Tennessee Research Foundation Lpa2 receptor agonist inhibitors of cftr
MX2008009579A (es) * 2006-01-27 2008-09-25 Univ Virginia Metodo para el tratamiento de dolor neuropatico.
EP1987013A1 (de) * 2006-02-09 2008-11-05 University Of Virginia Patent Foundation Bicyclische sphingosin-1-phosphat-analoge
EP2097371A2 (de) 2006-11-21 2009-09-09 University Of Virginia Patent Foundation Benzocycloheptyl-analoga mit sphingosin-1-phosphatrezeptor-aktivität
AU2007323618A1 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Tetralin analogs having sphingosine 1-phosphate agonist activity
JP2010510250A (ja) 2006-11-21 2010-04-02 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン=1−燐酸受容体アゴニスト活性を有するヒドリンダンアナログ
AU2008247488B2 (en) 2007-05-04 2014-02-27 Marina Biotech, Inc. Amino acid lipids and uses thereof
CN101358609A (zh) * 2007-08-03 2009-02-04 富准精密工业(深圳)有限公司 风扇转子
JP5692746B2 (ja) * 2008-08-07 2015-04-01 国立大学法人 長崎大学 全身性疼痛症候群の治療または予防薬
US9034820B2 (en) 2011-03-14 2015-05-19 Hsinyu Lee Method and composition for modulating erythropoiesis
KR20140067048A (ko) 2011-08-15 2014-06-03 인터뮨, 인크. 라이소포스파티드산 수용체 길항제
EP2858635A1 (de) * 2012-06-11 2015-04-15 The Regents of The University of California Inhibitoren des hippo-yap-signalweges
EP3089986B1 (de) * 2013-12-30 2019-06-26 Rxbio Inc. Kristalline salze von (z)-o-octadec-9-en-1-yl-o,o-dihydrogenphosphorothioat

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB861463A (en) 1957-05-03 1961-02-22 Ciba Ltd Process for the manufacture of phosphoric acid esters and piperazine and morpholine derivatives
US3639571A (en) 1970-01-29 1972-02-01 Samuel Turesky Composition and method for retarding plaque and dental calculus
JPS5687590A (en) * 1979-12-19 1981-07-16 Yoshitomi Pharmaceut Ind Ltd Diphosphoglycerine derivative
JPS59104310A (ja) * 1982-12-07 1984-06-16 Lion Corp 口腔用組成物
US4670575A (en) * 1984-06-05 1987-06-02 Kao Corporation Process for purification of phosphoric mono esters
EP0340759A1 (de) * 1988-05-06 1989-11-08 MAGIS FARMACEUTICI S.p.A. Salze von O-Mono(di)-acetyl-glycero-mono-(bis)-(di)-Phosphaten von L-Acetylcarnitin und von L-Acetylcarnitin-Estern
EP0425680A4 (en) 1989-02-28 1992-07-08 Teijin Limited New vitamin b 12? derivative, production thereof, and application thereof
JPH02250892A (ja) 1989-03-24 1990-10-08 Idemitsu Kosan Co Ltd 新規フェロセン誘導体,それを含有する界面活性剤及び有機薄膜の製造方法
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US5565439A (en) * 1992-11-24 1996-10-15 The Procter & Gamble Company Methods of using lysophosphatidic acid for treating hyperproliferative conditions
EP0692975A4 (de) 1993-04-08 2000-11-29 Univ Queensland Verabreichung eines vaso-aktiven wirkstoffes und eines therapeutischen wirkstoffes
US5480877A (en) * 1993-11-02 1996-01-02 Wisconsin Alumni Research Foundation Use of lysophosphatidic acids to enhance fibronectin binding
GB9618634D0 (en) 1996-09-06 1996-10-16 Univ Southampton Anti cancer drugs
WO1998041213A1 (en) 1997-03-19 1998-09-24 Lxr Biotechnology Inc. Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
CA2301921A1 (en) 1997-08-20 1999-02-25 John Graham Goddard Compositions containing polyethylene glycol and uses thereof
US5945522A (en) * 1997-12-22 1999-08-31 Genset Prostate cancer gene
EP1069895A4 (de) * 1998-03-18 2002-07-31 Lxr Biotechnology Inc Zusammenstellungen die lysophosphatidylsäure enthalten welche apoptosis hemmen und deren verwendungen
KR100874392B1 (ko) * 2000-03-17 2008-12-17 유니버시티 오브 테네시 리서치 파운데이션 Lpa 수용체 아고니스트 및 안타고니스트, 및 사용 방법

Also Published As

Publication number Publication date
KR20020082890A (ko) 2002-10-31
AU4926301A (en) 2001-10-03
CY1107214T1 (el) 2012-11-21
US20030027800A1 (en) 2003-02-06
CA2402038C (en) 2011-03-15
ES2298227T3 (es) 2008-05-16
WO2001071022A3 (en) 2002-04-04
EP1918287A3 (de) 2008-08-20
WO2001071022A2 (en) 2001-09-27
DE60131730T2 (de) 2008-11-20
EP1918287A2 (de) 2008-05-07
KR100874392B1 (ko) 2008-12-17
EP1263752A4 (de) 2003-07-30
US6875757B2 (en) 2005-04-05
JP2004506604A (ja) 2004-03-04
DE60131730D1 (de) 2008-01-17
CA2402038A1 (en) 2001-09-27
EP1263752B1 (de) 2007-12-05
DK1263752T3 (da) 2008-04-14
EP1263752A2 (de) 2002-12-11
PT1263752E (pt) 2008-03-18
US20050261252A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
DE60131730D1 (de) Agonisten und antagonisten für den lpa-rezeptor und anwendungsmethoden
DE60222396D1 (de) N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
ATE318267T1 (de) Einige alkylendiamin-substituierte heterocyclen
ATE433447T1 (de) Pyrimiidinverbindungen
ATE349434T1 (de) Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten
ATE299494T1 (de) Carbamat-derivate als muscarin-rezeptor antonisten
ATE446303T1 (de) Agonisten und antagonisten von sphingosin-1- phosphatrezeptoren
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
ES2243579T3 (es) Derivados de pirazolopirideno.
ATE440827T1 (de) Melanocortin-rezeptormodulatoren
ES2172585T3 (es) Derivado de benzoimidazol.
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
ATE540044T1 (de) Lpa-rezeptor-agonisten und antagonisten und verwendungsverfahren dafür
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
DE69935670D1 (de) Behandlung von dyskinesie durch mu-selektive opioidantagonisten
ATE354802T1 (de) Methoden zum screening knochenmorphogenetishemimetika
TR200002932T2 (tr) Azabisayklik 5HT1 Alıcı liganolları
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
DE60327375D1 (de) Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten
DE60222465D1 (de) Pyrazolopyridin-derivate als antiherpesmittel
ATE496896T1 (de) 1h-imidazolderivate als modulatoren des cannabinoidrezeptors
BR0317377A (pt) Derivados de 5-aminofenantridina como antagonistas de npy-5
ECSP993208A (es) Antagonistas de 5ht1 para terapia antidepresiva

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1263752

Country of ref document: EP

REN Ceased due to non-payment of the annual fee